Biotech partner drops GlaxoSmithKline’s adjuvant as it moves Covid-19 vaccine into PhII/III, citing ‘manufacturing considerations’
When GlaxoSmithKline revealed that its Sanofi-partnered recombinant protein-based Covid-19 vaccine program was running into a major delay, the pharma giant tucked in a paragraph noting the other lower-profile collaborations it had going on that utilized its pandemic adjuvant.
One of those partnerships, though, is now coming to an end.
China’s Clover Biopharmaceuticals — the first biotech to take up GSK’s offer to test its adjuvant system with vaccine candidates back in February — said it’s going to enter Phase II/III with an adjuvant from Dynavax instead.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
